How to Open a Dispensary in Australia (2026 Guide)

What “Dispensary” Means in Australia

In Australia, “dispensary” refers to pharmacy-led dispensing of prescribed medicinal cannabis. A patient is prescribed a product via the TGA’s (Therapeutic Goods Administration) Special Access or Authorised Prescriber routes (approved by active-ingredient category), and a pharmacist supplies it in accordance with federal guidance and state pharmacy rules.  Cannaspire’s Cannabis consultants support operators from application through daily operations.

Who does what?

• Clinics/Prescribers: Obtain SAS-B(Special Access Scheme Category B)/AP(Authorised Prescriber) approvals and issue prescriptions.
• Pharmacies: Verify TGA approval letter/category, check state dispensing obligations, and supply the product.
• Wholesalers/Importers/Manufacturers: Must meet TGA/ODC requirements for unapproved therapeutic goods (quality, supply chain, import/manufacture permissions).
• Cultivators/Researchers: Operate under ODC licences and permits issued per the Narcotic Drugs Act 1967. 

Cannabis Legalization Efforts

Australia’s framework in 2025 remains medical only at the national level. Efforts to change the law are active but uneven, with a defeated federal bill and a mix of state reviews, party proposals, and advocacy plans that explore decriminalisation or future regulated markets without creating retail access today.

• Federal (Commonwealth): The Legalising Cannabis Bill 2023 proposed a national adult-use framework via a Cannabis Australia National Agency; a Senate committee recommended not passing it in May 2024, and the Senate subsequently voted it down on 27 Nov 2024.
  
• New South Wales (NSW): A Legislative Council inquiry (Report 66, 20 Jun 2025) recommended a staged reform path, remove custodial penalties, then decriminalise, and ultimately move toward a regulated legal market; the government is considering the report.
  
• Western Australia (WA): The Greens (WA) released a state plan in Feb 2025 advocating legalisation and a regulated market.
• Victoria (VIC): Rank-and-file Liberal members pushed a non-binding motion (Sep 2025) to support a regulated adult-use market; reporting around the state council indicates the proposal was rejected amid broader internal debates.

Regulatory Framework 

Commonwealth (Federal)

• Therapeutic Goods Administration (TGA): Regulates importing, manufacturing, and supplying medicinal cannabis products (largely unapproved) and oversees prescriber access routes (SAS/AP). Also maintains product category lists to ensure prescription/approval alignment.
  
• Office of Drug Control (ODC): Administers licences and permits for cultivation, production, research, and manufacture under the Narcotic Drugs Act 1967, with defined application stages and expectations for processing.
  
• Border/Customs (Australian Border Force/Home Affairs): Enforces import/export controls consistent with TGA/ODC requirements. (Importers need the appropriate permissions and must meet product standards.)
  
• National Practitioner Regulators (Ahpra & Boards): Set expectations for safe prescribing and dispensing; recent advisories address poor practice and patient harm concerns in the sector.

Personal-Use Rules by Jurisdiction

State and territory governments control enforcement of personal possession laws, and approaches vary significantly. Some jurisdictions have introduced decriminalisation or diversion schemes, while others maintain strict prohibition. Importantly, these measures generally affect individual users rather than creating any form of retail or legal supply chain. Below is a breakdown:

• Australian Capital Territory (ACT): Since 2020 adults (18+) are allowed to possess up to 50 grams of dried cannabis (or equivalent wet quantity), and grow up to two plants per person (max four per household if more than two adults live there) in private. Sale or sharing, public consumption, and supply remain illegal.
• South Australia (SA): SA has de jure decriminalisation for possession of small amounts of cannabis. People caught with personal amounts may be fined rather than criminally prosecuted. Cultivation even of small amounts is still illegal unless expressly authorised.
• Northern Territory (NT): Like SA, NT has laws that allow fines rather than criminal penalties for small-quantity cannabis possession in some cases. These reflect in law decriminalisation in NT.
• New South Wales (NSW) — de facto diversion: Cannabis Cautioning Scheme lets police formally caution adults for minor cannabis offences instead of charging.
• Victoria (VIC) — de facto diversion: Cannabis cautioning program provides police cautions for simple use/possession of small amounts (non-trafficable), subject to eligibility.
• Queensland (QLD) — de facto diversion: Police Drug Diversion Program offers an alternative to prosecution for eligible personal-use possession; this does not decriminalise possession.
• Western Australia (WA) — de facto diversion: Cannabis Intervention Requirement (CIR) allows a notice and mandatory education session for eligible minor cannabis possession/use.

Medicinal Cannabis Licence Types in Australia

Clinic/Prescriber
Evaluate patients and access products through TGA’s Special Access Scheme (SAS-B) or Authorised Prescriber (AP) pathways; write prescriptions aligned to active-ingredient categories. 

Community/Specialty Pharmacy
Dispense prescribed medicinal-cannabis products in line with TGA approvals and state medicines/poisons rules; counsel patients; maintain dispensing records. 

Wholesaler/Distributor
Hold and supply scheduled products to pharmacies/clinics under medicines/poisons controls; maintain secure, quality-controlled distribution.

Importer
Bring finished products or materials into Australia under TGA/ODC permissions and Therapeutic Goods Order standards, then supply through approved channels.

Manufacturer
Produce finished therapeutic goods to GMP, meeting TGA licence/clearance and any ODC narcotic permissions applicable to cannabis substances.

Cultivator/Researcher
Grow and/or conduct research under ODC licences and permits made under the Narcotic Drugs Act 1967. 

Steps to Securing a Medicinal Cannabis Licence in Australia

1. Select role & pathway (SAS-B/AP, ODC, GMP/import).
   Decide whether you are entering as a clinician, pharmacy, wholesaler, importer, manufacturer, or cultivator/researcher. Match your role to the correct federal pathway:
   1. SAS-B / AP for prescribers
   2. ODC licensing for cultivation, production, or manufacturing involving narcotic substances
   3. TGA GMP/import permissions for manufacturing and importing therapeutic goods.
      This determines every other requirement downstream.
2. Review federal & state requirements.
   Map out all federal (TGA, ODC, Border/Customs) obligations plus jurisdiction-level medicines, poisons, pharmacy, and planning rules. Federal approvals control the product pathway; each state or territory sets additional dispensing, storage, and planning conditions for your premises.
3. Secure compliant premises & planning permissions.
   Before you apply, ensure your site can meet security, storage, zoning, and planning obligations. Requirements vary by role: pharmacies need dispensing security, wholesalers need controlled storage, and cultivators need restricted-site boundaries with ODC-standard security layouts.
4. Build quality systems (GMP/QMS, SOPs).
   Develop a Quality Management System covering Good Manufacturing Practice (GMP) for manufacturing, Good Distribution Practice (GDP) for wholesale, or clinical quality assurance for prescribing/dispensing. Document all procedures, roles, and records in SOPs and manuals.
5. Submit applications (TGA, ODC, state approvals).
   Prepare and lodge applications to the correct regulators:
   1. TGA for GMP licensing/clearance, SAS/AP authorisations, and product standards
   2. ODC for cultivation, manufacture, or narcotic permits
   3. State or territory health departments for dispensing, wholesale, and pharmacy obligations
6. Complete inspections & meet licence conditions.
   Regulators may conduct GMP audits, security inspections, or site assessments before granting approvals. Licences or permits are typically conditional, requiring you to implement specific safeguards before operations can commence.
7. Commence operations.
   Once approvals and conditions are satisfied, you can begin prescribing, dispensing, manufacturing, importing, or cultivating in line with your licensed scope. Ongoing compliance includes audits, licence renewals, and reporting obligations.

How Much Does It Cost To Open A Dispensary (Pharmacy) in Australia?

Opening a dispensary in Australia doesn’t involve a special “cannabis licence.” Pharmacies dispense medicinal cannabis under the same business and premises licences required for any pharmacy, along with medicines/poisons rules and TGA guidance. Here’s what that looks like:

1. Pharmacy business / premises licensing (jurisdictional):

Victoria (Victorian Pharmacy Authority):

• Annual licence (individual): AUD $425
  Annual licence (corporate): AUD $965
• Pharmacy business registration: AUD $400
  (Fees are fixed until 1 May 2026.)

Queensland (Pharmacy Business Ownership Council – from 1 July 2025):

• New licence application: $2,275–$3,309 (tiered)

• Annual renewal: $1,758–$2,585

• Licence fee: $414

• Adding a new person to licence: $931

2. e-Prescribing & Dispensing Software

• eRx Script Exchange: From 1 July 2025, a $0.15 fee per private prescription dispensed through eRx. (PBS prescriptions remain free.)

3. Secure Storage (Schedule 8 Controlled Drugs)

• Pharmacies must install compliant drug safes that meet strict security rules (anchoring, bolting, approved construction).
• No set fee nationally, but costs depend on the safe and installation work.

4. Premises Standards

• Pharmacies must meet minimum fit-out requirements (secure premises, dispensing area, private consultation space).
• Costs vary depending on build-out and location.

5. Other Costs

• Local council planning fees may apply (zoning, approvals).
• These vary by municipality and aren’t published in one schedule.

Australia does not have a separate national “dispensary licence” for retail cannabis; pharmacies dispense medicinal-cannabis products under existing pharmacy business licensing and medicines/poisons frameworks, plus TGA rules for prescription products. Local council planning fees may also apply but vary by municipality and are not centrally published. (The regulatory context for dispensing medicinal cannabis is set by TGA/jurisdiction health guidance.)

Costs & Capital (Ranges & Drivers)

What really drives costs up or down?
Expect costs across five buckets: 

1. Regulatory fees tied to your pathway (e.g., prescriber approvals, manufacturing GMP licensing/clearance, import permissions) 
2. Premises & security fit-out proportional to risk class and any Schedule 8–level storage needs 
3.  Quality & compliance setup (QMS, validation, audits)
4.  Software stack (e-prescribing/dispensing, inventory with batch traceability, recall readiness)
5. People & insurance (clinical, QA, RP/technical, PI/product liability, cyber). Capex skews to site build, controlled storage, and initial QMS; Opex skews to audits, licence maintenance, consumables, cold chain, training, and insurance. Regulatory time and inspection cycles are major multipliers: TGA processes for GMP licensing/clearance and ODC licensing/permits introduce sequencing that affects timeline and cash flow.

Communications & Advertising Rules

Boundaries set by law: Consumer promotion of prescription-only and unapproved therapeutic goods (including most medicinal-cannabis products) is prohibited. You may only advertise such products exclusively to health professionals under the Therapeutic Goods Act and Advertising Code. AHPRA’s National Law advertising rules also apply to any regulated health service messaging (e.g., no testimonials, no misleading claims). Recent enforcement shows regulators are actively pursuing unlawful cannabis advertising. For compliant posture: keep patient-facing content educational and non-promotional, route product specifics to HCP-only channels, and separate B2B technical materials from B2C patient education. 

Final Thoughts

Opening a medicinal-cannabis dispensary or pharmacy in Australia requires navigating multiple layers of regulation including federal TGA and ODC requirements, jurisdictional medicines and poisons laws, and local planning approvals. The process involves much more than securing a licence because compliance also covers site selection, quality systems, security, and ongoing operational reporting.

As of 2026, Australia remains a medical-only market with no legal recreational retail. Success depends on aligning your business model with patient access pathways, prescriber networks, and supply-chain compliance.

The key takeaway is to treat cannabis compliance as strategic investments rather than administrative hurdles. Getting them right protects both your operations and your patients. Our cannabis compliance services cover SOPs, GMP readiness, and ongoing monitoring.